GO
Loading...

Enter multiple symbols separated by commas

Teva Pharmaceutical Industries Ltd

More

  • Mylan to submit formal offer for Perrigo Friday, 24 Apr 2015 | 11:39 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Mylan announced Friday morning that it had commenced a formal offer to acquire Perrigo for a mix of cash and stock.

  • NEW YORK— Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low.

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • Mylan planning new offer for Perrigo: Source Wednesday, 22 Apr 2015 | 10:01 AM ET
    Tablets manufactured by Perrigo

    After its unsolicited takeover bid was denied, Mylan plans to make a new offer for Perrigo, according to a source familiar with the matter.

  • April 22- Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV. Meanwhile, Canonsburg, Pennsylvania- based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter...

  • Teva's turnaround CEO sets sights on $40 bln mega-deal Wednesday, 22 Apr 2015 | 9:06 AM ET

    TEL AVIV, April 22- Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries, is looking to pull off the ultimate transformation, with the biggest deal in Israel's corporate history. His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug...

  • FACTBOX-Teva Pharmaceutical's history of key acquisitions Wednesday, 22 Apr 2015 | 9:06 AM ET

    April 22- Teva Pharmaceutical Industries has offered to buy rival generic drugmaker Mylan for $40 billion in what would be the largest acquisition in Israel's history, equivalent to nearly 15 percent of GDP. *In March 2015 it said it would buy U.S. neurology drug company Auspex Pharmaceuticals for an equity value of $3.5 billion, a move to boost its portfolio of...

  • *Greece default worries keep investors on edge. NEW YORK, April 21- Major U.S. stock indexes lost ground on lackluster earnings reports on Tuesday, while oil fell on concerns about U.S. crude stockpiles and Saudi Arabia's announcement that it ended its military campaign in Yemen. But many investors held back as they waited for more quarterly reports and 2015...

  • Perrigo rejects $205/share bid from Mylan Tuesday, 21 Apr 2015 | 4:26 PM ET

    April 21- Dublin- based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company. Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros acquisition of Omega Pharma and new products that are expected to generate about $1...

  • Perrigo board unanimously rejects Mylan proposal Tuesday, 21 Apr 2015 | 4:04 PM ET
    Perrigo facility in Allegan, Michigan

    Perrigo announced Tuesday that its board of directors unanimously rejected the unsolicited bid from Mylan.

  • A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed, mostly failing to hold momentum from Monday, as investors reacted to individual earnings reports of major companies.

  • April 21- Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and...

  • TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. on Tuesday proposed buying smaller rival Mylan for $40 billion, saying it was a better deal than Mylan's alternate offer to buy Perrigo Co. Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the...

  • UPDATE 1-Teva makes $82 per share offer for Mylan Tuesday, 21 Apr 2015 | 8:57 AM ET

    TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash.

  • Teva makes $40B bid for Mylan Tuesday, 21 Apr 2015 | 8:49 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10.

  • Teva considering bid for Mylan: Report Friday, 17 Apr 2015 | 2:31 PM ET
    An employee collects newly-manufactured pills from a machine at the tablet production plant at Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel.

    Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.

  • Big pharma M&A may keep booming, CEOs say Thursday, 16 Apr 2015 | 3:44 PM ET
    Generic copies of Merck & Co.'s cholesterol pill Zocor and Pfizer Inc.'s Zoloft antidepressant.

    For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • Cramer Remix: This stock may be ready to break out Thursday, 9 Apr 2015 | 7:04 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer turns your attention to a social star that may be ready to roar.

  • Mylan seeks to buy Perrigo for $205 per share Wednesday, 8 Apr 2015 | 11:40 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Perrigo shares shot higher after news that Mylan proposed to buy Perrigo for $205 per share.